Sapoval, Marc R.
Bhatia, Shivank
Déan, Carole
Rampoldi, Antonio
Carnevale, Francisco César
Bent, Clare
Tapping, Charles R.
Bongiovanni, Simone
Taylor, Jeremy
Brower, Jayson S.
Rush, Michael
McWilliams, Justin P.
Little, Mark W.
,
Pellerin, Olivier
Barbosa, Fabiane
Borghei, Peyman
Gin, Greg E.
Uchio, Edward
Plotnik, Adam N.
Briggs, James H.
MacDonald, Andrew
Tummala, Srini
Shah, Hemendra Navinchandra
Kably, Issam M.
Pereira, Keith
Katrivesis, James
Ng, Keng Lim
Vaheesan, Kirubahara
Behdad, Mina
MacGill, Sarah
Crosbie, Sarah
Gavrila, Madita
Anthony, Susan
Quezada, Lia
Aleman, Ricardo
Ferguson, Cynthia Toot
Ahmed-Timms, Far
Edwards, Alexandra
Clinical trials referenced in this document:
Documents that mention this clinical trial
Two-Year Outcomes of Prostatic Artery Embolization for Symptomatic Benign Prostatic Hyperplasia: An International, Multicenter, Prospective Study
https://doi.org/10.1007/s00270-024-03802-0
Funding for this research was provided by:
Merit Medical Systems
Article History
Received: 1 February 2024
Accepted: 25 June 2024
First Online: 4 September 2024
Declarations
:
: Marc R. Sapoval has received consulting fees from Merit Medical Systems, Inc.; Shivank Bhatia is a consultant and stock owner in Embolx, and has received research funding from Merit Medical Systems, Inc.; Carole Déan has received consulting fees from Merit Medical Systems, Inc.; Charles R. Tapping has received honoraria from Merit Medical Systems, Inc., and Boston Scientific is a consultant and proctor for Sirtex Medical; Justin P. McWilliams is a consultant for Asahi Intecc and Johnson & Johnson, lecturer for Penumbra Medical, Terumo Medical, and Siemens Medical; Mark W. Little is a consultant for Merit Medical Systems, Inc., Boston Scientific, Guerbet, Varian Medical, Crannmed, and Microbot; Antonio Rampoldi, Francisco César Carnevale, Clare Bent, Simone Bongiovanni, Jeremy Taylor, Jayson S. Brower, and Michael Rush have nothing to disclose.
: Consent for publication was obtained for every individual person’s data included in the study.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.
: Institutional review board approval was obtained from all participating centers prior to the initiation of the study. All patients provided written informed consent to participate in the study.
: A synopsis of a portion of the study results was presented at the 2022 Global Embolization and Oncology Symposium Technologies (GEST) conference.